A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients

Veliparib (ABT‐888) is a poly(ADP‐ribose) polymerase inhibitor in development for the treatment of high‐grade ovarian cancer or BRCA‐mutated breast cancer in combination with carboplatin and paclitaxel. The population pharmacokinetics of veliparib were characterized using combined data from 1470 adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Stodtmann, Sven, Nuthalapati, Silpa, Eckert, Doerthe, Kasichayanula, Sreeneeranj, Joshi, Rujuta, Bach, Bruce A., Mensing, Sven, Menon, Rajeev, Xiong, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453554/
https://www.ncbi.nlm.nih.gov/pubmed/33894017
http://dx.doi.org/10.1002/jcph.1875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453554/
https://www.ncbi.nlm.nih.gov/pubmed/33894017
http://dx.doi.org/10.1002/jcph.1875

Ejemplares similares